Use of cardioprotective medications in kidney transplant recipients

Academic Article


  • Death with function causes half of late kidney transplant failures, and cardiovascular disease (CVD) is the most common cause of death in these patients. We examined the use of potentially cardioprotective medications in a prospective observational study at seven transplant centers in the United States and Canada. Among 935 patients, 87% received antihypertensive medications at both 1 and 6 months after transplantation. Similar antihypertensive regimens were used for patients with and without diabetes and CVD, but with wide variability among centers. In contrast, while 44% of patients were on angiotensin converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB) at the time of transplantation, the proportion taking these agents dropped to 12% at month 1, then increased to 24% at 6 months. Fewer than 30% with CVD or diabetes received ACEI/ARB therapy 6 months posttransplant. Aspirin use was uncommon (<40% of patients). Even among those with diabetes and/or CVD, fewer than 60% received aspirin and only half received a statin at 1 and 6 months. This study demonstrates marked variability in the use of cardioprotective medications in kidney transplant recipients, a finding that may reflect, among several possible explanations, clinical uncertainty due the lack of randomized trials for these medications in this population. © 2009 The American Society of Transplantation and the American Society of Transplant Surgeons.
  • Authors

    Published In

    Digital Object Identifier (doi)

    Author List

  • Gaston RS; Kasiske BL; Fieberg AM; Leduc R; Cosio FC; Gourishankar S; Halloran P; Hunsicker L; Rush D; Matas AJ
  • Start Page

  • 1811
  • End Page

  • 1815
  • Volume

  • 9
  • Issue

  • 8